Melanoma Drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the melanoma drugs market heading? What are the commercial prospects for this market and related technologies? Visiongain’s new report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects.
Our new 215 page report provides 185 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Dr Jean-Pierre Bizzari, Global Head of Oncology, Celgene Corporation
• Dr Rosalie M. Luiten, Head of the Laboratory of Experimental Dermatology, Dept of Dermatology, Academic Medical Center, University of Amsterdam
You find prospects for key submarkets
In addition to analyses of the overall world market, you see revenue forecasts for these four submarkets to 2024:
• Chemotherapeutic melanoma drugs
• Kinase Inhibitors
• Immunotherapeutic melanoma drugs
• Other melanoma drugs
Drugs that can significantly increase disease-free and progression-free survival while also improving patient tolerance will achieve success. Combination therapies aimed at attacking melanoma from multiple angles will prove successful in providing added benefits to patients and manufacturers.
Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find the dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for products
How will leading drugs perform to 2024 at the world level? How will promising products currently in the pipeline perform once they are launched? Our study forecasts sales of 14 melanoma products including these:
• Dabrafenib (Tafinlar)
• Trametinib (Mekinist)
• Vemurafenib (Zelboraf)
• Ipilimumab (Yervoy)
• PegIntron (Sylatron)
• Proleukin (Aldesleukin)
• Pembrolizumab (Keytruda)
• Binimetinib
• Cobimetinib
• Tasigna
• Temodar
• Nivolumab
• T-Vec
• Abraxane
Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.
What are the prospects for the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:
• US
• Australia
• Japan
• Germany
• France
• UK
• Italy
• Spain
• Brazil
• Russia
• India
• China
• Turkey
• Rest of the World
Our analyses show sustained growth, particularly for the markets with high predisposition factors to melanoma such as in Australia, Europe, and the Americas. New product approvals and the development of innovative targeted therapies will influence market growth.
Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.
Leading companies and potential for market growth
Overall world revenue for melanoma drugs will reach $2bn in 2014, our work forecasts. Rising demand for melanoma drugs, expanding healthcare coverage, recently launched therapies and a strong R&D pipeline will increase sales to 2024.
Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:
• Bayer AG
• Bristol Myers Squibb
• GSK
• Merck
• Prometheus Laboratories
• Roche
A company profile gives you the following information:
• Recent financial results
• Discussions of a company’s activities and outlook, including oncology product portfolios and pipelines
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Research and development activities
What is happening in the R&D pipeline for melanoma drugs? You see developmental trends, gaining insight into the R&D pipeline for:
• Kinase inhibitors for melanoma
• Immunotherapeutic agents for melanoma
• Vaccines for melanoma
• Genetic therapies for melanoma
• Other therapies for melanoma treatment
What issues will affect the melanoma drugs market?
Our new report discusses issues and events affecting the melanoma drugs market. You will find discussions of many issues and developments, including:
• Reimbursement, regulations, patent expiries, generic competition
• Cost savings and efficiencies
• The use of biologics, targeted and combination therapies
• Understanding melanoma aetiology and progression
• Safety and patient compliance
• Clinical evidence supporting product efficacy
Our investigation gives you multi-level business research and analyses with sales forecasts. You see how that industry and market can perform from 2014 to 2024.
How the Melanoma Drugs Market Forecast 2014-2024: Opportunities for Leading Companies report helps you
In summary our 215 page report gives you the following knowledge:
• Revenue forecasts to 2024 for the overall melanoma drugs market and 4 submarkets – discover the industry’s prospects, finding promising areas for investments and revenues
• Predicted revenues for 14 melanoma drugs – discover prospects for leading products in the market and promising therapies in the pipeline, with forecasted revenues provided to 2024
• Revenue forecast to 2024 for 13 leading national markets – US, Japan, Germany, France, the UK, Italy, Spain, Australia, Brazil, Russia, India, China, Turkey, and Rest of the World
• Evaluation of pipeline drugs – find the market potential for leading products currently in the development pipeline in each market segment
• Assessment of 6 leading companies – hear about products, results and strategies, including recent activities and outlook for companies such as Merck, Novartis, GSK, Bristol Myers Squibb, and Roche
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• Opinions from our survey, seeing interviews with industry authorities
You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for melanoma drugs. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Melanoma Drugs: Market Overview
1.2 Global Melanoma Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Cancer, Melanoma, and Melanoma Treatments
2.1 Cancer: Physiology, Causes, And Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness And Metastasis
2.1.4 Causes Of Cancer
2.2 Melanoma: A Brief Introduction
2.2.1 Causes Of Melanoma
2.2.2 Symptoms And Appearances Of Melanoma
2.3 Stages Of Melanoma
2.3.1 Early Stage Melanoma
2.3.2 Medium Stage Melanoma
2.3.3 Advanced Melanoma
2.4 The Incidence and Outlook for Melanoma – Global Trends
2.5 Surgery As A Treatment For Melanoma
2.6 The Use Of Radiotherapy In Melanoma Treatment
2.7 Drug Treatments In Melanoma
2.7.1 Traditional Chemotherapy
2.7.2 Immunotherapy
2.7.2.1 Monoclonal Antibodies (mAbs)
2.7.2.2 Cancer Vaccines
2.7.2.3 Non-Specific Immunotherapies
2.8 Market Definition
3. World Melanoma Drugs Market, 2014-2024
3.1 Global Melanoma Drugs: Market Overview
3.1.1 Categorisation Of The Global Melanoma Drugs Market
3.2 The Global Melanoma Market In 2013
3.2.1 Market Dominance Of Immunotherapeutic Drugs And Targeted Therapies
3.3 Global Melanoma Drugs: Market Forecast 2014-2024
3.3.1 Market Sectors That Will Drive Growth
3.3.2 Global Melanoma Drugs Market - Changing Market Shares By Sector 2014-2024
4. Kinase Inhibitors For Melanoma: World Market Analysis and Forecast, 2014-2024
4.1 The Global Market For Melanoma Kinase Inhibitors, 2013
4.1.1 Melanoma Kinase Inhibitors: Global Market Forecast 2014-2024
4.1.2 Melanoma Kinase Inhibitors - Changing Market Shares By Leading Drugs 2014-2024
4.2 Dabrafenib (Tafinlar) – GlaxoSmithKline
4.2.1 Dabrafenib (Tafinlar) – Sales Forecast, 2014-2024
4.3 Trametinib (Mekinist) – GlaxoSmithKline
4.3.1 Trametinib (Mekinist) – Sales Forecast 2014-2024
4.4 Vemurafenib (Zelboraf) – Roche/ Genentech/ Chugai/ Daiichi Sankyo
4.4.1 Vemurafenib (Zelboraf) – Historical Sales Analysis, 2011-2013
4.4.2 Vemurafenib (Zelboraf) – Sales Forecast 2014-2024
4.5 The Market For Other Kinase Inhibitors In Melanoma
4.5.1 Other Kinase Inhibitors – Sales Forecast 2014-2024
5. Immunotherapeutic Agents For Melanoma: World Market Analysis and Forecast, 2014-2024
5.1 The Global Market For Immunotherapeutic Agents In Melanoma, 2013
5.1.1 Melanoma Immunotherapeutic Agents: Global Market Forecast 2014-2024
5.1.2 Melanoma Immunotherapeutic Agents - Changing Market Shares By Leading Drugs 2014-2024
5.2 Ipilimumab (Yervoy) – Bristol Myers Squibb
5.2.1 Ipilimumab (Yervoy) – Historical Sales Analysis, 2011-2013
5.2.2 Ipilimumab (Yervoy) – Sales Forecast 2014-2024
5.3 PegIntron (Peginterferon Alpha-2b; Sylatron, IntronA) – Merck
5.3.1 PegIntron – Historical Sales Analysis, 2011-2013
5.3.2 PegIntron – Sales Forecast 2014-2024
5.4 Proleukin (Aldesleukin) – Prometheus Laboratories/ Novartis
5.4.1 Proleukin (Aldesleukin) – Historical Sales Analysis, 2011-2013
5.4.2 Proleukin (Aldesleukin) – Sales Forecast 2014-2024
5.5 Keytruda (Pembrolizumab) - Merck
5.5.1 Patent Disputes Over Keytruda
5.5.2 Keytruda (Pembrolizumab) – Sales Forecast 2014-2024
5.6 The Market For Other Immunotherapeutic Agents In Melanoma
5.6.1 Other Immunotherapeutic Agents – Sales Forecast 2014-2024
6. Chemotherapeutic Agents For Melanoma: World Market Analysis and Forecast, 2014-2024
6.1 The Global Market For Melanoma Chemotherapeutic Agents, 2013
6.1.1 Melanoma Chemotherapeutic Agents: Global Market Forecast 2014-2024
6.2 Dacarbazine (DTIC-Dome) - Bayer
6.2.1 Possible Combination Therapies Involving Dacarbazine
6.3 Temodar/Temodal (Temozolomide) – Merck
6.3.1 Temodar/Temodal (Temozolomide) – Historical Sales Analysis, 2011-2013
6.3.2 Temodar/Temodal (Temozolomide) – Sales Forecast 2014-2024
6.4 Other Chemotherapeutic Agents In Melanoma Treatment
6.4.1 Cisplatin (Platinol)
6.4.1.1 Cisplatin (Platinol) – Historical Sales Analysis, 2010-2012
6.4.2 Fotemustine
6.4.3 Bleomycin (Blenoxane)
6.4.4 Other Chemotherapeutic Agents – Sales Forecast 2014-2024
7. Leading National Markets for Melanoma Drugs, 2014-2024
7.1 The Melanoma Drugs Market By Region
7.1.1 The Global Distribution of Melanoma Drugs In 2013
7.2 Leading National Markets: Forecast 2014-2024
7.2.1 Changing Market Shares By Region, 2014-2024
7.3 Regional Melanoma Drugs Markets: Analysis And Forecasts, 2014-2024
7.4 United States: The Largest Melanoma Drug Market
7.4.1 US Melanoma Drugs Market: Market Forecast 2014-2024
7.5 The EU5 Markets: Growth Expected In Each Country
7.5.1 EU5 Melanoma Drugs Market: Market Forecast 2014-2024
7.5.1.1 EU5 Markets: Changing Market Shares By Country, 2014-2024
7.5.2 Germany: New Reforms To Medicinal Pricing May Impact Market Entry
7.5.2.1 German Melanoma Drugs Market: Market Forecast 2014-2024
7.5.3 France: Changing Drug Approval Process May Delay Regulatory Submissions
7.5.3.1 French Melanoma Drugs Market: Market Forecast 2014-2024
7.5.4 UK: Cost-Effectiveness Measures Impacting Growth
7.5.4.1 UK Melanoma Drugs Market: Market Forecast 2014-2024
7.5.5 Italy: Economic Recovery To Boost Future Of Oncology
7.5.5.1 Italian Melanoma Drugs Market: Market Forecast 2014-2024
7.5.6 Spain: High Level Of Patient Needs Will Counter Healthcare Rationalisation Measures
7.5.6.1 Spain Melanoma Drugs Market: Market Forecast 2014-2024
7.6 Australia: Highest Melanoma Incidence Rate Globally
7.6.1 Australian Melanoma Drugs Market: Market Forecast 2014-2024
7.7 Japan: Openness To Innovation Will Drive Revenue Increase
7.7.1 Japanese Melanoma Drugs Market: Market Forecast 2014-2024
7.8 China: Heavy Reliance On Traditional Herbal Remedies
7.8.1 Chinese Melanoma Drugs Market: Market Forecast 2014-2024
7.9 India: Contrasting Effects Of A Growing Population And Weak IP Protection
7.9.1 Indian Melanoma Drugs Market: Market Forecast 2014-2024
7.10 Brazil: Political Mandates And Economic Development Will Stimulate Growth
7.10.1 Brazilian Melanoma Drugs Market: Market Forecast 2014-2024
7.11 Turkey: Population Growth And Migration Will Be Tools For Growth
7.11.1 Turkish Melanoma Drugs Market: Market Forecast 2014-2024
7.12 Russia: High Income Nation With Low Per-Capita Healthcare Spending
7.12.1 Russian Melanoma Drugs Market: Market Forecast 2014-2024
7.13 Rest of the World
7.13.1 Rest of the World Melanoma Drugs Market: Market Forecast 2014-2024
8. Leading Companies In The Melanoma Drugs Market, 2014
8.1 Melanoma Drugs Market: A Highly Dynamic Market Space
8.2 Bayer AG
8.2.1 Bayer Oncology Drug Portfolio, 2014
8.2.2 Bayer Oncology Drug Pipeline, 2014
8.3 Bristol Myers Squibb
8.3.1 Bristol Myers Squibb: Oncology Drug Portfolio, 2014
8.3.2 Bristol Myers Squibb: Oncology Development Pipeline, 2014
8.4 GlaxoSmithKline (GSK)
8.4.1 GSK: Oncology Drug Portfolio, 2014
8.4.2 GSK: Oncology Development Pipeline, 2014
8.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.5 Merck
8.5.1 Merck: Oncology Drugs Portfolio, 2014
8.5.2 Merck: Oncology Development Pipeline, 2014
8.6 Prometheus Laboratories
8.6.1 Prometheus Laboratories: Oncology Portfolio, 2014
8.7 Roche
8.7.1 Roche: Oncology Portfolio, 2014
8.7.2 Roche: Oncology Development Pipeline, 2014
9. Melanoma Drugs: R&D Pipeline, 2014-2024
9.1 Innovative Products Currently In Development Will Drive Growth
9.1.1 Co-Developments And Collaborations Are Crucial For Market Growth
9.2 Developmental Pipeline - Kinase Inhibitors For Melanoma, 2014
9.2.1 Binimetinib (MEK162) – Novartis
9.2.1.1 Binimetinib (MEK162) – Sales Forecast 2014-2024
9.2.2 Cobimetinib - Exelixis /Genentech/ Roche
9.2.2.1 Co-Development And Licensing Agreements For Cobimetinib
9.2.2.2 Clinical Trials And Development Efforts For Cobimetinib
9.2.2.3 Cobimetinib – Sales Forecast 2014-2024
9.2.3 Encorafenib (LGX818) - Novartis
9.2.4 Tasigna (Nilotinib) - Novartis
9.2.4.1 Tasigna - Indications And Market Exclusivity
9.2.4.2 Tasigna In Melanoma
9.2.4.3 Tasigna (Nilotinib) – Sales Forecast 2014-2024
9.3 Developmental Pipeline - Immunotherapeutic Agents In Melanoma, 2014
9.3.1 Genasense (Oblimersen Sodium) - Genta Incorporated
9.3.2 INCB024360 – Incyte Corporation
9.3.3 MEDI4736 – AstraZeneca/ MedImmune
9.3.4 MPDL3280A – Roche/Genentech
9.3.5 Nivolumab (Opdivo) – Bristol Myers Squibb/ Ono Pharmaceutical
9.3.5.1 Nivolumab (Opdivo) – Sales Forecast 2014-2024
9.4 Developmental Pipeline - Vaccine Therapies In Melanoma, 2014
9.4.1 Astuprotimut-R (MAGE-A3 ASCI) - GlaxoSmithKline
9.4.1.1 Clinical Trials And Development Efforts For Astuprotimut
9.4.2 CDX-1401 – Celldex Therapeutics
9.4.3 Talimogene Laherparepvec (T-Vec) - Amgen
9.4.3.1 Clinical Trials And Development Efforts For T-Vec
9.4.3.2 Talimogene Laherparepvec (T-Vec) – Sales Forecast 2014-2024
9.5 Developmental Pipeline - Genetic Therapies In Melanoma, 2014
9.5.1 Allovectin-7 (Velimogene Aliplasmid) - Vical Incorporated
9.5.1.1 Allovectin-7 – Trial Setbacks And Efficacy Issues
9.5.2 Dorgenmeltucel-L – NewLink Genetics Corporation
9.5.2.1 Clinical Trials And Development Efforts For Dorgenmeltucel-L
9.6 Developmental Pipeline - Other Therapies In Melanoma, 2014
9.6.1 Abraxane - Celgene Corporation
9.6.1.1 Clinical Trials And Development Efforts For Abraxane
9.6.1.2 Abraxane – Sales Forecast 2014-2024
9.6.2 Autologous Dendritic Cell-Tumour Cell Immunotherapy – NeoStem
10. Qualitative Analysis for the Global Melanoma Drugs Market, 2014-2024
10.1 Market Factors Influencing The Melanoma Drugs Market
10.2 SWOT Analysis Of The Melanoma Drugs Market, 2014-2024
10.2.1 Strengths
10.2.1.1 Promising Pipeline Candidates Expected To Boost Product Choice And Competitiveness
10.2.1.2 Stratifying Patients Offers Clinical and Commercial Benefits
10.2.1.3 Improved Patient Compliance Offer Added Incentive For Growth
10.2.2 Weaknesses
10.2.2.1 Disease Recurrence And Low Disease Free Survival May Hinder Investments
10.2.2.2 High Development Costs Making Break-Even A Bigger Challenge For Marketed Drugs
10.2.2.3 The Complexity Of Melanoma’s Aetiology
10.2.3 Opportunities
10.2.3.1 Rising Melanoma Incidence Amidst A Rising Global Population Will Stimulate Growth
10.2.3.2 A Shift Towards Personalisation
10.2.3.3 Combination Therapies Bring Additive Benefits
10.2.3.4 Commercial Success Leveraged By Clinical Benefit
10.2.4 Threats
10.2.4.1 Inadequate Reimbursement Levels: Drug Pricing Creating Constraints On Market Growth
10.2.4.2 Melanoma Drugs Face The Prospect Of Generic Erosion Over Time
10.3 Porter’s Five Force Analysis Of The Melanoma Drugs Market, 2014-2024
10.3.1 Threat Of New Entrants: Medium
10.3.2 Threat Of Substitutes: Low
10.3.3 Power Of Suppliers: Medium
10.3.4 Power Of Buyers: Low
10.3.5 Rivalry Among Competitors: Medium
11. Expert Opinions from Our Primary Research
11.1 Interview With Dr Jean-Pierre Bizzari, Global Head Of Oncology, Celgene Corporation
11.1.1 Targeted Therapies And Immune Checkpoints Are Areas For Accelerated Development
11.1.2 The Economic Implications Of Patient Segmentation And Targeted Therapies
11.1.3 On The Possible Combination Between Celgene’s Abraxane And Bristol Myers Squibb’s Nivolumab
11.1.4 On Celgene’s Strategy For Success In Oncology
11.1.5 On The Current Challenges In Oncology And The Possible Solutions To Be Implemented
11.1.6 On Work Being Done to Map Signalling Pathways And Exploit Cellular Mechanisms For Drug Development
11.1.7 The Future Impact Of Regulatory Hurdles and Trial Design On Survival Advantage
11.2 Interview With Dr Rosalie M. Luiten PhD, Head of the Laboratory of Experimental Dermatology, Dept of Dermatology, Academic Medical Center, University of Amsterdam
11.2.1 Stages Of Melanoma And The Currently Available Treatment Options
11.2.2 Recent Developments In Targeted Therapies For Melanoma
11.2.3 Combination Therapies And The Challenge To Increase Durable Response Rate
11.2.4 On The Current Treatment Options For Early Stage Melanoma
11.2.5 On The Rising Popularity Of Immune Checkpoint Blockade In Oncology
11.2.6 Monobenzone Therapy And Its Potential Use As A Melanoma Therapy
11.2.7 On The Interactions Between Monobenzone And Immune Activating Compounds
11.2.8 Future Plans For Monobenzone Therapy As A Melanoma Treatment
11.2.9 On The Link Between Vitiligo And Melanoma
11.2.10 On The Future Trend Of ‘Per-Patient’ Treatment Approaches To Melanoma
12. Conclusions
12.1 Overview Of Current Market Conditions And Market Forecast, 2013-2024
12.2 The US To Remain As The Largest Market
12.3 Australia And Evolving Markets In Countries Such As Brazil And Turkey Will Stimulate Growth
12.4 Personalisation And Targeted Treatments Will Dominate
12.5 Strong Development Pipeline Will Be Crucial To Future Growth
List of Tables
Table 1.1 US Melanoma Incidence and Mortality: Breakdown by Age-Group (%), 2007-2011
Table 1.2 Redacted German Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 1.3 Redacted Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
Table 2.1 The Clark Scale For Grading Melanoma, 2014
Table 2.2 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2014
Table 2.3 Cancer-Treating Agents: Immunotherapies and Targeted Therapies, 2014
Table 3.1 The Global Melanoma Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2013
Table 3.2 The Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2013-2024
Table 3.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2018, 2018-2024, 2013-2024
Table 3.4 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
Table 3.5 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2013, 2018, 2024
Table 4.1 The Global Market for Melanoma Kinase Inhibitors: Revenue ($m) and Market Shares (%) For Leading Drugs, 2013
Table 4.2 Global Melanoma Kinase Inhibitors: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 4.3 The Global Melanoma Kinase Inhibitors Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 4.4 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 4.5 Dabrafenib (Tafinlar): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.6 Trametinib (Mekinist): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.7 Vemurafenib (Zelboraf): Historical Sales ($m, AGR%), 2011-2013
Table 4.8 Vemurafenib (Zelboraf): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.9 Other Kinase Inhibitors Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.1 The Global Market for Melanoma Immunotherapeutic Agents: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 5.2 Global Melanoma Immunotherapeutic Agents: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 5.3 The Global Melanoma Immunotherapeutic Agents Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 5.4 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 5.5 Ipilimumab (Yervoy): Historical Sales ($m, AGR%), 2011-2013
Table 5.6 Ipilimumab (Yervoy): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.7 PegIntron (Sylatron): Historical Sales ($m, AGR%), 2011-2013
Table 5.8 PegIntron (Sylatron): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.9 Proleukin (Aldesleukin): Historical Sales ($m, AGR%), 2011-2013
Table 5.10 Proleukin (Aldesleukin): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.11 Keytruda (Pembrolizumab): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.12 Other Immunotherapeutic Agents: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.1 The Global Market for Melanoma Chemotherapeutic Agents: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 6.2 Global Melanoma Chemotherapeutic Agents: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 6.3 Temodar/Temodal (Temozolomide): Historical Sales ($m, AGR%), 2011-2013
Table 6.4 Temodar/Temodal (Temozolomide): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.5 Cisplatin (Paraplatin): Historical Sales ($m, AGR%), 2010-2012
Table 6.6 Other Chemotherapeutic Agents: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.1 The Global Melanoma Drugs Market: Market Size ($m) and Market Share (%) by Region, 2013
Table 7.2 Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
Table 7.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2018, 2018-2024, and 2013-2024
Table 7.4 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2013, 2018, and 2024
Table 7.5 US Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.6 US Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.7 EU5 Melanoma Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
Table 7.8 The EU5 Melanoma Drugs Market: Revenue ($m) and Market Share (%) by Country, 2013
Table 7.9 EU5 Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.10 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2013, 2018, 2024
Table 7.11 The German Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.12 The German Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.13 The French Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.14 The French Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.15 The UK Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.16 The UK Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.17 The Italian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.18 The Italian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.19 The Spanish Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.20 The Spanish Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.21 The Australian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.22 The Australian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.23 The Japanese Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.24 The Japanese Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.25 The Chinese Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.26 The Chinese Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.27 The Indian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.28 The Indian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.29 The Brazilian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.30 The Brazilian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.31 The Turkish Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.32 The Turkish Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.33 The Russian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.34 The Russian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.35 The Rest of the World Melanoma Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
Table 7.36 The Rest of the World Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.1 Bayer: Overview, 2014
Table 8.2 Bayer: Oncology Portfolio, 2014
Table 8.3 Bayer: Oncology Development Pipeline, 2014
Table 8.4 Bristol Myers Squibb (BMS): Overview, 2014
Table 8.5 Bristol Myers Squibb: Oncology Portfolio, 2014
Table 8.6 Bristol Myers Squibb: Oncology Development Pipeline, 2014
Table 8.7 GlaxoSmithKline (GSK): Overview, 2014
Table 8.8 GlaxoSmithKline (GSK): Oncology Portfolio, 2014
Table 8.9 GlaxoSmithKline (GSK): Oncology Pipeline, 2014
Table 8.10 Merck: Overview, 2014
Table 8.11 Merck: Oncology Portfolio, 2014
Table 8.12 Merck: Oncology Pipeline, 2014
Table 8.13 Prometheus Laboratories: Overview, 2014
Table 8.14 Prometheus Laboratories: Drug Portfolio, 2014
Table 8.15 Roche: Overview, 2014
Table 8.16 Roche: Oncology Portfolio, 2014
Table 8.17 Roche: Oncology Pipeline, 2014
Table 9.1 R&D Pipeline For Kinase Inhibitors In Melanoma, 2014
Table 9.2 Binimetinib (MEK162): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.3 Cobimetinib: Potential Combination Therapies, 2014
Table 9.4 Cobimetinib: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.5 Tasigna (Nilotinib): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.6 R&D Pipeline For Immunotherapeutic Agents In Melanoma, 2014
Table 9.7 Nivolumab (Opdivo): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.8 R&D Pipeline For Vaccine Therapies In Melanoma, 2014
Table 9.9 Talimogene Laherparepvec (T-Vec): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.10 R&D Pipeline For Genetic Therapies In Melanoma, 2014
Table 9.11 R&D Pipeline For Other Therapies In Melanoma Treatment, 2014
Table 9.12 Abraxane: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 10.1 Melanoma Drugs: Market Drivers and Restraints 2014-2024
Table 10.2 SWOT Analysis of the Melanoma Drugs Market, 2014-2024
Table 12.1 Global Melanoma Drugs: Market Forecast ($m, CAGR%), 2013, 2018, 2021, 2024
Table 12.2 Global Melanoma Drugs: Market Shares (%) by Region, 2013, 2018, 2021, 2024
Table 12.3 Global Melanoma Drugs: Market Forecast ($m) by Sector, 2013, 2018, 2021, 2024
List of Figures
Figure 1.1 US Melanoma Incidence and Mortality: Breakdown by Age-Group (%), 2007-2011
Figure 1.2 Global Melanoma Drugs Market: Submarkets, 2014
Figure 3.1 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013
Figure 3.2 The Global Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 3.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2018
Figure 3.4 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2018-2024
Figure 3.5 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2024
Figure 3.6 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
Figure 3.7 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2013
Figure 3.8 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2018
Figure 3.9 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2024
Figure 4.1 The Global Market for Melanoma Kinase Inhibitors: Revenue ($m) For Leading Drugs, 2013
Figure 4.2 Global Melanoma Kinase Inhibitors: Market Forecast ($m, AGR%), 2013-2024
Figure 4.3 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2013
Figure 4.4 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2018
Figure 4.5 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2024
Figure 4.6 Dabrafenib (Tafinlar): Sales Forecast ($m, AGR%), 2013-2024
Figure 4.7 Trametinib (Mekinist): Sales Forecast ($m, AGR%), 2013-2024
Figure 4.8 Vemurafenib (Zelboraf): Historical Sales ($m, AGR%), 2011-2013
Figure 4.9 Vemurafenib (Zelboraf): Sales Forecast ($m, AGR%), 2013-2024
Figure 4.10 Other Kinase Inhibitors: Sales Forecast ($m, AGR%), 2013-2024
Figure 5.1 The Global Market for Melanoma Immunotherapeutic Agents: Revenue ($m) by Leading Drugs, 2013
Figure 5.2 Global Melanoma Immunotherapeutic Agents: Market Forecast ($m, AGR%), 2013-2024
Figure 5.3 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2013
Figure 5.4 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2018
Figure 5.5 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2024
Figure 5.6 Ipilimumab (Yervoy): Historical Sales ($m, AGR%), 2011-2013
Figure 5.7 Ipilimumab (Yervoy): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.8 PegIntron (Sylatron): Historical Sales ($m, AGR%), 2011-2013
Figure 5.9 PegIntron (Sylatron): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.10 Proleukin (Aldesleukin): Historical Sales ($m, AGR%), 2011-2013
Figure 5.11 Proleukin (Aldesleukin): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.12 Keytruda (Pembrolizumab): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.13 Other Immunotherapeutic Agents: Sales Forecast ($m, AGR%), 2013-2024
Figure 6.1 The Global Market for Melanoma Chemotherapeutic Agents: Revenue ($m) by Leading Drugs, 2013
Figure 6.2 Global Melanoma Chemotherapeutic Agents: Market Forecast ($m, AGR%), 2013-2024
Figure 6.3 Temodar/Temodal (Temozolomide): Historical Sales ($m, AGR%), 2011-2013
Figure 6.4 Temodar/Temodal (Temozolomide): Sales Forecast ($m, AGR%), 2013-2024
Figure 6.5 Cisplatin (Paraplatin): Historical Sales ($m, AGR%), 2010-2012
Figure 6.6 Other Chemotherapeutic Agents: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.1 The Global Melanoma Drugs Market: Market Size ($m) by Region, 2013
Figure 7.2 US, EU5, Japan, and Australia Melanoma Drugs Market: Market Forecast ($m), 2013-2024
Figure 7.3 Brazil, Russia, India, China, and Turkey Melanoma Drugs Market: Market Forecast ($m), 2013-2024
Figure 7.4 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2018
Figure 7.5 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2018-2024
Figure 7.6 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2024
Figure 7.7 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2013
Figure 7.8 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2018
Figure 7.9 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2024
Figure 7.10 US Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.11 The EU5 Melanoma Drugs Market: Revenues ($m) by Country, 2013
Figure 7.12 Germany, France, UK, Italy, and Spain Melanoma Drugs Market: Market Forecast ($m), 2013-2024
Figure 7.13 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2013
Figure 7.14 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2018
Figure 7.15 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2024
Figure 7.16 The German Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.17 The French Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.18 The UK Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.19 The Italian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.20 The Spanish Melanoma Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.21 The Australian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.22 The Japanese Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.23 The Chinese Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.24 The Indian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.25 The Brazilian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.26 The Turkish Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.27 The Russian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.28 The Rest of the World Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.1 Binimetinib (MEK162): Sales Forecast ($m, AGR%), 2013-2024
Figure 9.2 Cobimetinib: Sales Forecast ($m, AGR%), 2013-2024
Figure 9.3 Tasigna (Nilotinib): Sales Forecast ($m, AGR%), 2013-2024
Figure 9.4 Nivolumab (Opdivo): Sales Forecast ($m, AGR%), 2013-2024
Figure 9.5 Talimogene Laherparepvec (T-Vec): Sales Forecast ($m, AGR%), 2013-2024
Figure 9.6 Abraxane: Sales Forecast ($m, AGR%), 2013-2024
Figure 10.1 Porter’s Five Force Analysis of the Melanoma Drugs Market, 2014
Figure 12.1 Global Melanoma Drugs: Market Forecast ($m), 2013, 2018, 2021, 2024
Figure 12.2 Top Selling Melanoma Drugs, 2013
Figure 12.3 Global Melanoma Drugs: Market Forecast ($m) by Sector, 2013-2024
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
